SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

casdozokitug

CHRS·Coherus Oncology, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Unclear. Casdozokitug is in Phase 2 development for hepatocellular carcinoma. No pivotal or registration-directed trial has been announced, and the program appears to have been deprioritized in favor of tagmokitug.
Why 3/10
No hard, dated binary catalyst (PDUFA, pivotal readout) is scheduled for casdozokitug in the next ~12 months. The original Phase 2 open-label study (NCT05359861) was terminated as of October 2026. A randomized Phase 2 study combining casdozokitug with toripalimab and bevacizumab in first-line HCC was initiated in December 2024, but no data readout date has been announced. The company's November 9, 2026 strategic prioritization plan focuses development on tagmokitug/toripalimab for esophageal cancer, suggesting casdozokitug is a lower priority.
Actionable Insight NEUTRAL

Watch for any update on the randomized Phase 2 study of casdozokitug + toripalimab + bevacizumab in first-line HCC, which was initiated in December 2024. The company's November 2026 strategic prioritization plan appears to focus on tagmokitug for esophageal cancer, so investors should monitor whether casdozokitug development continues or is formally deprioritized. The stock trades around $0.82 with a market cap near $156 million and has a mean analyst price target of $7.75, though coverage is stale (last analyst action August 2026).

Price Chart

Loading chart...

Executive Summary

Casdozokitug (also called casdozo, development code CHS-388) is a first-in-class IL-27-targeted antibody being developed by Coherus Oncology (CHRS) for hepatocellular carcinoma (HCC, the most common type of liver cancer). It was originally acquired through Coherus's September 2023 acquisition of Surface Oncology. Final Phase 2 data from an open-label study presented at ASCO-GI 2025 showed a 17.2% complete response rate and 38% objective response rate when combined with atezolizumab and bevacizumab. A randomized Phase 2 study combining casdozokitug with Coherus's own PD-1 inhibitor toripalimab (LOQTORZI) plus bevacizumab was initiated in December 2024. However, Coherus's November 9, 2026 strategic prioritization plan focuses development on tagmokitug/toripalimab for esophageal cancer, suggesting casdozokitug is a lower priority. The stock trades around $0.82 with a roughly $156 million market cap, well below the mean analyst price target of $7.75, though analyst coverage is stale.

How It Works

Casdozokitug is a monoclonal antibody that blocks IL-27, a protein that tumors use to suppress the immune system. By neutralizing IL-27, the drug aims to restore the immune system's ability to attack cancer cells. It is designed to be combined with other immunotherapies (PD-1/PD-L1 inhibitors) and VEGF blockers to create a multi-pronged attack on liver cancer.

Trial Status

An initial Phase 2 open-label study (NCT05359861) evaluating casdozokitug + atezolizumab + bevacizumab in HCC completed enrollment and reported final data at ASCO-GI 2025, showing a 17.2% complete response rate and 38% objective response rate. That study was terminated as of October 2026 per ClinicalTrials.gov. A separate randomized Phase 2 study of casdozokitug + toripalimab + bevacizumab in first-line unresectable HCC was initiated in December 2024; no results have been reported.

The Two-Sided Case

▲ Bull Case4
Casdozokitug is a first-in-class IL-27 antagonist with a novel mechanism that could address resistance to checkpoint inhibitors in HCC, a large market.
Final Phase 2 data showed a 17.2% complete response rate and 38% objective response rate in combination with atezolizumab/bevacizumab, which is notable in a difficult-to-treat cancer.
The randomized Phase 2 study combining casdozokitug with Coherus's own approved PD-1 inhibitor toripalimab could create a proprietary combination if successful.
Analyst consensus is bullish: 10 Buy/Strong Buy vs 2 Hold ratings, with a mean price target of $7.75 vs the current ~$0.82 stock price (though coverage is stale).
▼ Bear Case5
The original Phase 2 study (NCT05359861) was terminated as of October 2026, and the company's November 2026 strategic prioritization plan focuses on tagmokitug for esophageal cancer, suggesting casdozokitug has been deprioritized.
No pivotal or registration-directed trial has been announced, and no data readout date has been given for the randomized Phase 2 study.
Coherus has a small market cap (~$156 million) and limited commercial revenue (LOQTORZI sales of ~$14-15 million/quarter), raising questions about funding for multiple pipeline programs.
Institutional holders showed significant trimming in Q2 2026, with several large funds (SEI, Millennium, Citadel, Susquehanna) reducing positions by 60-93%.
The stock trades 61% below its 52-week high, and analyst coverage is stale (last action August 2026).

Upcoming Catalysts

  • Any update on the randomized Phase 2 study of casdozokitug + toripalimab + bevacizumab in first-line HCC
  • Clarity on whether casdozokitug remains an active development program following the strategic prioritization toward tagmokitug
  • Potential partnership or out-licensing of the asset if deprioritized

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Coherus Oncology, Inc. PRESS-RELEASE CHRS ·Originating report

Sources · 11

Hover a chip for the title
1 markets.businessinsider.com2 nasdaq.com3 nasdaq.com4 seekingalpha.com5 seekingalpha.com6 markets.businessinsider.com7 nasdaq.com8 ascopubs.org9 ad-hoc-news.de10 markets.financialcontent.com11 financialcontent.com